MRK logo

MERCK & CO. INC.

MRKNYSE
πŸ† #38 by market capEarnings Oct 29 Β· PreUS Equity
$146.74β–Ό $1.92 (βˆ’1.31%)
Live
πŸ””
Track MRK
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.3%
7dβ–Ό 2.9%
14dβ–² 2.1%
30dβ–Ό 1.1%
ytdβ–² 39.4%
1yβ–² 86.8%
🏦Market Cap
$362.42B
Large Cap
πŸ“ˆRevenue Growth (YoY)
+1.2%
Slowing
πŸ“ŠGross Margin
75.4%
High
πŸ’΅FCF Margin
24.2%
Strong
βš–οΈP/S Ratio
5.5x
Fair
Otter Score
64
Fair

Trading Snapshot

Day Range
$144.50 – $148.80
52-Week Range
$78.03 – $156.92
Volume
$9.96B
Avg Volume
$10.68B
Shares Outstanding
2.47B
Next Earnings
Nov 7, 2026

Fundamentals Snapshot

Annual Revenue
$64.93B
Last Q Revenue
$16.61B
P/E Ratio
118.0
P/S Ratio
5.5x
EPS (TTM)
$1.28
Dividend Yield
2.29%
Dilution (1yr)
βˆ’2.1%

Why Investors Own MRK

  • βœ“High-growth profile β€” revenue up +50.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 27% gross margin and 9% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

MRK logo

MERCK & CO. INC.

MRK
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$64.9Bβ–² +1.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
72.0%β–Ό βˆ’5.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$23.5Bβ–² +16.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$12.4Bβ–Ό βˆ’31.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
2.49Bβ–Ό βˆ’2.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$36.0Bβ–Ό βˆ’$10.9B YoY
StockOtter Β· stockotter.space

About MERCK & CO. INC.

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100

Analyst Ratings

β“˜
Consensus
Buy
36 analysts
Strong Buy8
Buy18
Hold10
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

πŸš€
Zacks Investment ResearchΒ·5h ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

πŸ›°οΈ
Zacks Investment ResearchΒ·1d ago

Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy

MRK and Daiichi withdraw an FDA filing for ifinatamab deruxtecan after data falls short, while late-stage studies continue.

🌌
Zacks Investment ResearchΒ·1d ago

FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication

FDA expands MRK's Welireg label for advanced kidney cancer, adding a third indication as sales climb and the drug gains wider use.

ReutersΒ·1d ago

US drugmakers turn to China for licensing deals

Merck on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global ​rights to an experimental cancer drug, making β€Œit the latest US drugmaker to license China-developed medicines.

ReutersΒ·1d ago

Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion

Merck said on Monday it would pay up to $2.13 billion under a ​global licensing deal with China's SciBrunch Therapeutics β€Œfor rights to develop, manufacture and sell an experimental cancer treatment.

Business WireΒ·1d ago

Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and SciBrunch Therapeutics Co., Ltd. (β€œSciBrunch”), today announced that they have entered into an exclusive global